MUDr. Dana Maňasková


Vyhledávání na medicinman.cz
 

potraviny/epilobii-herba/ucinky

Analgesic activity

  • Ethanolic tincture of E. angustifolium was evaporated to dryness (under vaccum at 45°C)
  • Resulting dry extract was resuspended in 3% propylene glycol-water mixture and tested
  • Concentrations of 0, 47.5, 95, 190, and 380 mg/kg bw were applied s.c. to Swiss ICR (CD1) male mice (about 30 g)
  • Analgesic effects in the writhing test, comparable to the reference lysine acetylsalicylate (300 mg/kg s.c.) [1]

Antidiarrhoeal activity (in vivo)

  • From the whole fresh plants of E. hirsutum, E. palustre, E. rosmarinifolium, E. spicatum and E. tetragonum
  • 4 different animal models for effects on the gastrointestinal tract
    • Charcoal meal in mice, castor oil-induced diarrhoea in mice, intestinal fluid accumulation in mice, activity of rabbit jejunum
  • Epilobium extracts showed antidiarrhoeal activity
    • Statistically significant from 25 mg/kg b.w. i.p
    • A decrease of intestinal transit (statistically significant from 50 mg/kg b.w. i.p)
    • no fluid intraluminal accumulation
    • Spontaneous and acetylcholine-induced contractions of the rabbit jejunum were inhibited. [1]

Antimicrobial activity

Different water-soluble extracts of E. angustifolium

(in vitro)
  • MIC values from 4.6 to 18.2 mg/ml were determined
  • no difference detected between flower- and leave-extracts.
  • Extracts of E. angustifolium were tested for antibacterial activity against
    • Staphylococcus aureus,
    • Micrococcus luteus,
    • Escherichia coli
    • Pseudomonas aeruginosa
  • Extract showed bacterial growth inhibition in all tested strains, comparable to or more effective than 250 microg/ml vancomycin and tetracycline [1]

Extracts of E. angustifolium, E. hirsutum, E. rosmarinifolium, E. palustre and E. tetragonum

  • Screened for antimicrobial activity in gram-positive as well as gram-negative bacteria, yeasts and fungi
  • Minimum inhibitory concentration (MIC) values and minimum cytocidal concentration (MCC) values
    • Determined between 10 and 650 microg/ml for the different extracts depending on the respective microorganism. [1]

Pharmacodynamic interactions

  • Both repression and induction of mRNA expression were observed in cytochormes
  • Kujawski et al. 2014 suggest that E. angustifolium extract may cause interactions with synthetic drugs used in the treatment of proliferative changes in hormone-dependent reproductive organs, but potential consequences are purely hypothetical [1]
  • Aqueous extract of Epilobium hirsutum Male Wistar albino rats
    • 37.5 mg/kg b.w. (i.p) of the dried extract for nine consecutive days
    • CYP1A1 and CYP2E1 levels were decreased
    • NQO1 and GPx increased after treatment
    • Implicate protection against possible reactive metabolites of drugs and chemicals [1]

Primary pharmacodynamics

  • Anti-proliferative activity
    • Potential effect on prostate cells growth
  • Anti-inflammatory activities
    • Primary pharmacodynamic effects in the treatment of symptoms related to benign prostatic hyperplasia.

Aqueous extracts of E. angustifolium, E. parviflorum, E. hirsutum

  • Cells were exposed to 20, 50, and 70 microg/ml of lyophylized aqueous extract (DER 4-5:1, extraction at 40°C)
  • In vitro, hormone dependent prostate cancer cells (LNCaP)
  • Stolarczyk et al. 2013a
  • Significant increase in the level of apoptotic cells via activation of the mitochondrial pathway

Aqueous extracts of E. angustifolium, E. parviflorum, E. hirsutum

  • Cells were exposed to 20, 50, and 70 microg/ml of lyophylized aqueous extract (DER 4-5:1, extraction at 40°C)
  • In vitro, hormone dependent prostate cancer cells (LNCaP)
  • Stolarczyk et al. 2013b
  • Inhibition of proliferation of LNCaP with IC50 values of 32.2 – 44.6 microg/ml, statistically significant reduction of PSA and inhibition of

Aqueous extracts of E. angustifolium, E. parviflorum, E. hirsutum

  • Ratio herbal substance:extraction solvent: 1:10
  • In vitro, antiinflammatory activity
    • Inhibition of hyaluronidase
    • Inhib. lipoxygenase;
  • Influence on elastase and myeloperoxidase release
  • Inhibition of hyaluronidase and lipoxygenase
    • With IC50 of 5 microg/ml and 25 microg/ml (extracts)
  • Inhibition of elastase release:
    • IC50 >50 microg/ml;
  • Inhibitoin of myeloperoxidase release IC50:
    • 26 microg/ml (E. hirsutum),
    • Over 50microg/ ml (E. parviflorum)
    • 34 microg/ml (E. angustifolium)

Aqueous and other extracts of E. angustifolium

  • Ratio herbal substance:
    • Extraction solvent: 1:10;
  • Concentrations of 25, 50, and 100 microg/ml were tested
  • In vitro, neutral endopeptidase (NEP) in prostate cancer cells (PC-3)
  • 2006a Induction of NEP in prostate cancer cells,
  • Weak but significant inhibition of cell proliferation

Aqueous extract of E. angustifolium

  • Ratio herbal substance: extraction solvent: 1:10
  • Concentrations of 25, 50, and 100 microg/ml were tested
  • Neutral endopeptidase (NEP) in prostate cancer cells (high expression SKN-H vs. low expression PC3)
  • Induction of NEP in prostate cancer cells
    • SK-N-H cells were much more suceptible

Aqueous extract of Epilobium parviflorum

  • Ratio herbal substance: extraction solvent: 1:10;
  • Concentration of 250 microg/ml of extract was tested;
  • Positive control: indomethacin
  • In vitro, COX-1 and COX-2 assay;
  • Inhibition of COX-1 (ca. 60%) and COX-2 (<10%) catalysed prostaglandin biosynthesis

Aqueous extracts of E. parviflorum

  • Fractionated extraction (ligroin, CHCl3, MeOH, H2O)
  • In vitro 90% inhibition of 5-alpha-reductase at 10microl

Aqueous extracts of E. angustifolium

  • Ratio herbal substance: extraction solvent; 1:15;
  • Dosage: 40mg/kg/day for 20 days Route of administration: p.o.
  • In vivo; Antiandrogen assay on intact male Wistar rats and testosterone stimulated castrated male Wistar rats
  • Impact on growth of accessory sexual organs was observed:
    • Significant inhibitory effect on weight of seminal vesicles (antiandrogen effect) in intact animals;
    • Increase of weight of prostate, seminal vesicles and musculus laevator ani (pro-androgen effect)

Parviflorum solvent:

  • 1:50 and 1:30;
  • Dosage: 1 ml (corresponding to 33mg/ml dry herb per 100 g body weight)
  • Reduced PG-release
  • Was strongly anti-inflammatory in the paw oedema model (comparable to indomethacin 2 mg/kg/p.o)

Extract of E. parviflorum

  • Was less potent in reducing PG release
  • Inactive in the paw oedema model

Aqueous-acetone extract of Epilobium parviflorum

  • Extraction solvent Aqueous acetone (80% V/V) In vitro;
  • Decreased PGE2 release (IC50 1.4±0.1microg/ml)
    • Comparable to the positive control indomethacin Ethanolic extract of Epilobium angustifolium
  • Cells were exposed to 19, 190, and 1900 microg of dry extract per ml medium
  • In vitro, human prostatic epithelial cells (PZ-HPV-7), MTT-assay Vitalone et al. 2001

Ethanolic extract of Epilobium parviflorum

  • Anti-proliferative effect was observed at the highest concentration after 24 and 48h
  • Ratio herbal substance: extraction solvent: 1:10;
  • Concentration of 250 microg/ml of extract was tested
  • In vitro, COX1- and COX-2inhibition assay
  • Indomethacin Steenkamp et al. 2006 Inhibition of COX-1 (ca. 98%) and COX-2 (ca. 60%) catalysed prostaglandin biosynthesis

Oenothein B

  • Cells were exposed to 0, 10, 20, and 40 microg/ml of oenothein B
  • Cells were exposed to 20 microg/ml of oenothein B
  • In vitro, lymphocytes (human, bovine) Ramstead et al. 2012
    • Stimulation of innate lymphocytes, NK cells;
    • Enhancement of the production of IFNgamma
  • Oenothein B Cells were exposed to solutions of 10, 20, and 40 microM In vitro, hormone dependent prostate cancer cells (LNCaP) Stolarczyk et al. 2013b
    • Inhibition of proliferation of LNCaP with an IC50 value of 7.8 microM
      • Statistically significant reduction of PSA and inhibition of arginase activity [1]
  • Oenothein B In vitro,
    • Antiinflammatory activity;
    • Human neutrophils (inhibition of hyaluronidase, lipoxygenase, influence on elastase and myeloperoxida se release)
      • Inhibition of hyaluronidase and lipoxygenase with IC50 of 1.1microM; elastase release: no inhibition; myeloperoxidase release: IC50 7.7microM
  • Oenothein B
    • Cells were exposed to solutions of 10, 20, and 40 microM In vitro,
    • Neutral endopeptidase (NEP) in prostate cancer cells (PC-3)
    • Induction of NEP in prostate cancer cells, weak but significant inhibition of cell proliferation
  • Oenothein B
    • PC-3 cells were exposed to solutions of 10, 20, and 40 microM
    • SK-N-H cells to solutions of 5, 10, and 20 microM
  • Oenothein B In vitro
    • Neutral endopeptidase (NEP), angiotensin converting enzyme (ACE),
    • Inhibition of both metallopeptidases ACE: IC50 250 microM NEP: IC50 20 microM
  • Oenothein A
    • 70% inhibition of aromatase at 50microM; 5alpha-Reductase: IC50 1.24 microM
  • Oenothein B
    • 33% inhibition of Aromatase at 50microM; 5-alpha-Reductase: IC50 0.44microM
  • Oenothein B
    • Inhibition of 5-alpha-reductase: IC50 0.22 microM

Urolithins A, B, and C (metabolites of oenothein B)

    • Cells were exposed to solutions of 10, 20, and 40 microM In vitro,
    • Hormone dependent prostate cancer cells (LNCaP)
      • Inhibition of proliferation of LNCaP with IC50 values of 35.2 – 40 microM,
      • Statistically significant reduction of PSA and inhibition of arginase activity

Myricetin-3-O-beta-Dglucuronide

    • Rat paw oedema: Dosage: 0.04, 0.2 and 1.0 mg/kg body weight In vivo,
    • Carrageenan induced oedema in the Hiermann et al. 1991
    • Strong antiinflammatory effect (0.2 mg/kg/b.w.)

Quercetion-3glucuronide, quercetin3O-(6’’-galloyl)galactoside

  • PC-3 cells were exposed to solutions of 100 microM, and SK-NH cells to solutions of 25, 50, and 100 microM In vitro,
  • Neutral endopeptidase (NEP) in prostate cancer cells (high expression SKN-H vs. low expression PC3)
  • Induction of NEP in prostate cancer cells, SK-N-SK cells were much more suceptible

Fertility, pregnancy and lactation

  • No data available.
  • The use in pregnancy and lactation is not applicable due to the indication. [1]
O úroveň výše

Poslední aktualizace: 18. 10. 2019 0:51:55